Sharp Therapeutics Corp.
SHRXF
$1.00
$0.4375.72%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.00% | 4.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | -15.87% | |||
| Operating Income | 0.00% | 15.87% | |||
| Income Before Tax | 0.00% | 48.84% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.00% | 48.84% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | 48.84% | |||
| EBIT | 0.00% | 15.87% | |||
| EBITDA | 0.00% | 15.82% | |||
| EPS Basic | 0.00% | 52.73% | |||
| Normalized Basic EPS | 0.00% | 42.19% | |||
| EPS Diluted | 0.00% | 52.95% | |||
| Normalized Diluted EPS | 0.00% | 42.19% | |||
| Average Basic Shares Outstanding | 0.00% | 8.18% | |||
| Average Diluted Shares Outstanding | 0.00% | 8.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||